Bronwyn Bosch
Johannesburg, GT, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Journal: Open forum infectious diseases
Published: August 21, 2023
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.
Journal: Frontiers in reproductive health
Published: December 29, 2022
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 12, 2022
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.
Journal: AIDS (London, England)
Published: September 29, 2022
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.
Journal: Open forum infectious diseases
Published: August 05, 2022
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Journal: The Journal of antimicrobial chemotherapy
Published: March 07, 2022
Weight gain stopping/switch rules for antiretroviral clinical trials.
Journal: AIDS (London, England)
Published: December 01, 2021
Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 02, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026